X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Average Rating of “Moderate Buy” by Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $28.8750.

Several analysts have commented on the stock. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 26th. Stifel Nicolaus set a $10.00 target price on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, Guggenheim started coverage on X4 Pharmaceuticals in a research note on Monday, March 9th. They set a “buy” rating and a $12.00 price target for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of XFOR. Indivisible Partners purchased a new position in shares of X4 Pharmaceuticals in the fourth quarter valued at $40,000. Rhumbline Advisers raised its stake in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals during the third quarter valued at $47,000. Squarepoint Ops LLC bought a new position in X4 Pharmaceuticals during the fourth quarter valued at $50,000. Finally, Stifel Financial Corp purchased a new position in shares of X4 Pharmaceuticals in the 4th quarter worth $82,000. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals News Summary

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Brookline materially improved its FY2026 EPS view (from -$1.50 to -$1.04), a smaller near‑term loss that suggests a faster path toward profitability. Brookline Cap M FY2026 estimate
• Positive Sentiment: Brookline raised its FY2027 EPS forecast (from -$1.70 to -$0.96), reducing multi‑year downside and improving the medium‑term outlook. Brookline Cap M FY2027 estimate
• Positive Sentiment: Brookline lifted its FY2028 estimate (from -$0.42 to -$0.24), another sign of improving expected margins in later years. Brookline Cap M FY2028 estimate
• Positive Sentiment: Brookline published a long‑range FY2030 EPS projection of $2.85, signaling significant upside potential if X4 hits longer‑term commercialization and scaling assumptions. Brookline Cap M FY2030 estimate
• Neutral Sentiment: Brookline provided updated quarterly EPS forecasts for 2026 (Q1: -$0.20, Q2: -$0.23, Q3: -$0.27, Q4: -$0.34) that set expectations for near‑term performance but are routine analyst guidance updates rather than company‑driven news. Brookline Cap M quarterly estimates
• Negative Sentiment: Brookline cut its FY2029 EPS forecast sharply (from $1.52 to $0.85), lowering medium‑term upside and indicating the analyst reduced confidence in the timing/scale of revenue or margin improvements for that year. Brookline Cap M FY2029 revision

X4 Pharmaceuticals Price Performance

XFOR stock opened at $4.28 on Friday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $9.56. The company’s fifty day moving average price is $3.67 and its 200-day moving average price is $3.62. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.48 and a current ratio of 10.16. The company has a market capitalization of $389.14 million, a PE ratio of -0.99 and a beta of 0.43.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its earnings results on Tuesday, March 17th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.14. The firm had revenue of $2.57 million during the quarter, compared to analyst estimates of $1.68 million. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 115.27%. On average, equities analysts anticipate that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.